ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Multicentric Study of Cytomegalovirus Resistance in Transplant Patients and Bone Marrow Recipients (PHRC CMV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01008540
Recruitment Status : Completed
First Posted : November 6, 2009
Last Update Posted : September 5, 2016
Sponsor:
Information provided by (Responsible Party):
University Hospital, Limoges

Brief Summary:
The investigators aim is to determine the incidence of cytomegalovirus resistance to antivirals in a cohort study. The patients are included at their first CMV active infection and are followed during two years thereafter. When criteria for suspected resistance are meet, blood and urine samples are collected for virus isolation and further resistance phenotype, and for resistance genotype determination. Results are compared with baseline samples. Clinical information such as treatment, immunosuppressive regimen and clinical evolution will be collected. Through this study, the investigators aim to organize a national network for the detection and identification of CMV resistant strains that will be useful when new therapeutics will be available.

Condition or disease Intervention/treatment Phase
Cytomegalovirus Biological: depistage Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 800 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Cytomegalovirus Resistance in Transplant Patients and Bone Marrow Recipients in the Prophylaxis Era, a French Multicentric Cohort Study
Study Start Date : August 2006
Actual Primary Completion Date : December 2010
Actual Study Completion Date : June 2012

Intervention Details:
  • Biological: depistage
    Virus isolation from urine, blood, or any suitable sample in case of CMV disease Resistance phenotype to antivirals UL97 and UL54 genes sequencing from blood, urines or any suitable samples for resistance mutations detection and polymorphism study


Primary Outcome Measures :
  1. Resistance incidence in our patients with subgroup analysis, by organ and by the use of prophylaxis or preemptive treatment

Secondary Outcome Measures :
  1. Strain diversity in baseline isolates and in resistant isolates Frequency of known resistance mutations Identification of new resistance-related mutations.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Allogeneic bone marrow transplant recipient or solid organ transplant recipient, included in the cohort at the time of its firs active CMV infection (ie biological signs of CMV replication (viremia, ADN or ARN aemia, Antigenaemiapp65….) with or without fever, or clinical end organ disease symptoms

Exclusion Criteria:

  • Patient without medical care.policy,
  • patient that did not signed the médical consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01008540


Locations
France
Virologie
Amiens, France, 80
Virologie
Angers, France, 49
Virologie
Besancon, France, 25
Virologie - Hôpital Avicenne
Bobigny, France, 93
Virologie
Bordeaux, France, 33
Virologie
Brest, France, 29
Virologie
Caen, France, 14
Virologie
Clermont Ferrand, France, 63
Virologie
Dijon, France, 21
Virologie
Fort de France, France, 97
Virologie
Grenoble, France, 38
Virologie
Lille, France, 59
Bactériologie Virologie
Limoges, France, 87042
Virologie
Lyon, France, 69
Virologie
Montpellier, France, 34
Virologie
Nancy, France, 54
Virologie
Nantes, France, 44
Virologie
Nimes, France, 30
Virologie - Hôpital BICHAT
Paris, France, 75
Virologie - Hôpital La Pitié Salpétrière
Paris, France, 75
Virologie - Hôpital LARIBOISIERE
Paris, France, 75
Virologie - Hôpital NECKER
Paris, France, 75
Virologie - Hôpital SAINT-LOUIS
Paris, France, 75
Virologie
Poitiers, France, 86
Virologie
Reims, France, 51
Virologie
Rennes, France, 35
Virologie
Rouen, France, 76
Virologie
Saint-etienne, France, 42
Virologie
Strasbourg, France, 67
Virologie
Suresne, France, 92
Virologie
Toulouse, France, 31
Virologie
Tours, France, 37
Virologie - Hôpital Paul Brousse
Villejuif, France, 94
Sponsors and Collaborators
University Hospital, Limoges
Investigators
Principal Investigator: ALAIN Sophie, MD University Hospital, Limoges